Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tenaya Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TNYA
Nasdaq
8731
https://www.tenayatherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tenaya Therapeutics Inc
Institutions own 33% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares but private equity firms control 44% of the company
- Apr 14th, 2024 1:50 pm
20 Countries with the Highest Heart Disease Deaths Per Capita
- Mar 26th, 2024 11:19 am
Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results
- Mar 20th, 2024 9:32 am
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 18th, 2024 8:05 pm
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
- Mar 18th, 2024 12:30 pm
14 Stocks With Heavy Insider Buying In 2024
- Feb 29th, 2024 8:02 am
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
- Feb 27th, 2024 9:30 pm
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
- Feb 26th, 2024 2:55 pm
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
- Feb 26th, 2024 1:30 pm
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
- Feb 9th, 2024 2:55 pm
Tenaya Therapeutics Announces Pricing of Underwritten Offering
- Feb 8th, 2024 1:00 pm
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
- Jan 26th, 2024 5:00 pm
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 1:30 pm
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
- Nov 21st, 2023 9:30 pm
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 8th, 2023 9:05 pm
Institutional investors have a lot riding on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) with 38% ownership
- Nov 6th, 2023 1:20 pm
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
- Oct 26th, 2023 12:30 pm
We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully
- Oct 10th, 2023 11:52 am
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
- Oct 9th, 2023 12:30 pm
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
- Oct 5th, 2023 12:30 pm
Scroll